Cantor Fitzgerald set a $20.00 price target on Opko Health, Inc. (NASDAQ:OPK) in a report released on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on OPK. Ladenburg Thalmann Financial Services reissued a buy rating and set a $19.50 price target on shares of Opko Health in a research report on Friday, June 16th. BidaskClub raised Opko Health from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. Zacks Investment Research raised Opko Health from a sell rating to a hold rating in a research report on Wednesday, July 12th. Barrington Research raised their target price on Opko Health to $11.00 and gave the company an outperform rating in a report on Tuesday, July 18th. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $8.00 target price on shares of Opko Health in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $13.97.

Shares of Opko Health (OPK) opened at 6.95 on Thursday. Opko Health has a one year low of $5.85 and a one year high of $12.15. The firm’s market cap is $3.89 billion. The stock’s 50 day moving average price is $6.56 and its 200 day moving average price is $6.70.

Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company had revenue of $314.20 million for the quarter, compared to the consensus estimate of $322.64 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. The firm’s revenue for the quarter was down 12.0% on a year-over-year basis. On average, equities analysts anticipate that Opko Health will post ($0.20) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Opko Health, Inc. (OPK) a $20.00 Price Target” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/16/cantor-fitzgerald-analysts-give-opko-health-inc-opk-a-20-00-price-target.html.

In other news, CEO Phillip Md Et Al Frost purchased 5,400 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was bought at an average cost of $6.46 per share, for a total transaction of $34,884.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $19,825,423.46. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders bought a total of 924,000 shares of company stock valued at $5,657,033 over the last quarter. 40.19% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Eqis Capital Management Inc. grew its holdings in Opko Health by 28.5% during the 3rd quarter. Eqis Capital Management Inc. now owns 51,135 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 11,354 shares during the period. Piedmont Investment Advisors LLC grew its holdings in Opko Health by 43.4% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 230,643 shares of the biotechnology company’s stock worth $1,518,000 after acquiring an additional 69,818 shares during the period. Psagot Investment House Ltd. grew its holdings in Opko Health by 20.0% during the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 3,806 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 1,657 shares during the period. Finally, State Street Corp grew its holdings in Opko Health by 3.9% during the 2nd quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock worth $74,671,000 after acquiring an additional 422,203 shares during the period. Hedge funds and other institutional investors own 22.45% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.